

Curriculum vitae

Name	Andreas Kerschbaumer
Address	Medical University of Vienna, Department of Medicine III, Division of Rheumatology Währinger Gürtel 18-20, 1090, Vienna, Austria
E-mail	andreas.kerschbaumer@meduniwien.ac.at
Birthdate	18.01.1990
Citizenship	Austria



Education

03/2018 – today	Medical doctor (Fellow): Internal medicine and rheumatology (ÄAO2015)
10/2016 – today	Doctoral/PhD program (N094), Medical University of Vienna “Arthritis MetaAnalysis Database”
10/2010 – 07/2016	Human medicine (N202), Medical University of Vienna Thesis: „Serum Complement C3 as a Possible Disease Activity Marker in Psoriatic Arthritis”

Work experience

03/2018 – today	Medical doctor (Resident): Internal medicine and rheumatology (ÄAO2015) <i>MUV – Vienna General Hospital, Department of Medicine III, Rheumatology</i> Residency: Rheumatologic ward and outpatients clinic, Nephrology, Infectiology, Bone marrow transplantation Clinical science: chronic inflammatory arthritides, database management, teaching of medical students, mentoring of diploma students.
10/2016 – 02/2018	Scientific employee <i>MUV – Vienna General Hospital, Department of Medicine III, Rheumatology</i> Clinical science (outcomes research, systematic literature reviews, meta-analyses), database development and -management, sub-investigator in clinical trials

Taskforces / Memberships

- 11/2022 – today **EULAR Taskforce: EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2023 Update** – Fellow
- 10/2020 – today **Taskforce on development of treat to target (T2T) recommendations for giant cell arteritis and polymyalgia rheumatica** – Co-Methodologist
- 06/2018 – today **The Rheumatology Expert Group (TREG)** – International faculty
- 2021 – 2022 **EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update** – Fellow, SLR on treatment efficacy
- 2020 – 2022 **Taskforce on the consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions** – Co-Methodologist
- 2019 – 2021 **EULAR Taskforce: Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis** – Co-Methodologist
- 2018 – 2019 **Consensus statement: Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors** – Fellow
- 2018 –2019 **EULAR Taskforce: EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update** – Fellow
- 2018 – 2019 **EULAR Taskforce: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update** – Fellow, SLR on treatment efficacy

Publications (selection)

- Kerschbaumer A, Stimakovits NM, Smolen JS, Stefanova T, Chwala E, Aletaha D. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis. *Ann Rheum Dis*. 2023 Jan 10;ard-2022-223349. doi: 10.1136/ard-2022-223349. Epub ahead of print. PMID: 36627167.
- Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis*. 2022 Nov 11;ard-2022-223365. doi: 10.1136/ard-2022-223365. Epub ahead of print.
- Kerschbaumer A, Rivai ZI, Smolen JS, et al. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. *Ann Rheum Dis*. 2022 Jun 20;annrheumdis-2021-221807. doi: 10.1136/annrheumdis-2021-221807.
- Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. *RMD Open* 2020;6. doi:10.1136/rmdopen-2020-001374
- Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological Treatment of Psoriatic Arthritis: A Systematic Literature Research for the 2019 Update of the EULAR Recommendations for the Management of Psoriatic Arthritis. *Annals of the Rheumatic Diseases* 2020 Jun;79(6):778-786. doi: 10.1136/annrheumdis-2020-217163.
- Kerschbaumer A, Smolen JS, Herkner H, et al. Efficacy Outcomes in Phase 2 and Phase 3 Randomized Controlled Trials in Rheumatology. *Nature Medicine*. 2020 Apr 20. doi: 10.1038/s41591-020-0833-4.
- Kerschbaumer A, Aletaha D. Targeting p19 in Psoriatic Arthritis: More Than Just Another Therapeutic Approach? *Lancet*. 2020 Apr 4;395(10230):1091-1093. doi: 10.1016/S0140-6736(20)30525-0.
- Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases*. Published Online First: 07 February 2020. doi: 10.1136/annrheumdis-2019-216656
- Aletaha D, Kerschbaumer A, Smolen JS. Tofacitinib for Psoriatic Arthritis. *New England Journal of Medicine*. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189.
- Kerschbaumer A, Baker D, Smolen JS, Aletaha D. The effects of structural damage on functional disability in psoriatic arthritis. *Annals of the Rheumatic Diseases*. 2017 Dec;76(12):2038–2045.